Full Text View
Tabular View
No Study Results Posted
Related Studies
Development of Serologic Assays for Human Herpes Virus-8
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), September 2006
First Received: October 31, 2006   Last Updated: November 2, 2006   History of Changes
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00395278
  Purpose

Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of Kaposi's sarcoma, an AIDS-defining condition). We initially plan to examine samples from patients with Kaposi's sarcoma, since all those patients are almost certainly infected with HHV-8. We are thus using samples from patients with previously diagnosed Kaposi's sarcoma. The samples in question are stored at the NCI FCRF repository operated by SAIC Frederick or in Rockville, MD.


Condition
Human Herpes Virus-8

MedlinePlus related topics: Kaposi's Sarcoma Soft Tissue Sarcoma
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History
Official Title: Development of Serologic Assays for Human Herpes Virus-8

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 100
Study Start Date: October 2006
Estimated Study Completion Date: September 2006
Detailed Description:

Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of Kaposi's sarcoma, an AIDS-defining condition). We initially plan to examine samples from patients with Kaposi's sarcoma, since all those patients are almost certainly infected with HHV-8. We are thus using samples from patients with previously diagnosed Kaposi's sarcoma. The samples in question are stored at the NCI FCRF repository operated by SAIC Frederick or in Rockville, MD.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

-Data analysis only.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00395278

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

No publications provided

Study ID Numbers: 999907018, 07-CC-N018
Study First Received: October 31, 2006
Last Updated: November 2, 2006
ClinicalTrials.gov Identifier: NCT00395278     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
KSHV
Kaposi's Sarcoma
HIV

Study placed in the following topic categories:
Virus Diseases
Soft Tissue Sarcomas
Malignant Mesenchymal Tumor
HIV Infections
Sarcoma, Kaposi
Acquired Immunodeficiency Syndrome
Sarcoma
Kaposi Sarcoma

ClinicalTrials.gov processed this record on May 07, 2009